NASH is a worldwide epidemic disease affecting over 115 million people. Still, NASH remains an underdiagnosed and consequently an underreported disease. Untreated NASH may lead to cirrhosis, liver cancer and liver transplantation.
Our mission
The Swiss NASH Foundation is a non-for-profit organization committed to the dissemination of knowledge and raising of awareness about NASH. Through funding cutting edge research projects and increasing the knowledge and awareness about NASH, the foundation aims at contributing to treatment discovery as well as improving the patients’ quality of life.
Our history
In a joint effort to tackle the increasing prevalence and burden of NASH, scientific experts and the leading pharmaceutical companies: Gilead, Allergan, Genfit and Intercept have joined forces to establish The Swiss NASH Foundation.
Our vision
Prevent, diagnose and cure NASH.
Find out more
Swiss NASH Foundation: Mission and goals
News
- A Breakthrough in Liver Metabolic Health: Inside Survodutide’s Phase 3 SYNCHRONIZE-MASLD Trial ResultsAsk the author session The global landscape of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), is evolving… Read more: A Breakthrough in Liver Metabolic Health: Inside Survodutide’s Phase 3 SYNCHRONIZE-MASLD Trial Results
- Unlocking Precision Medicine in Metabolic Health: Why GLP-1 Agonist Responses Vary and How AI is Solving the PuzzleAsk the author session Glucagon-like peptide-1 receptor (GLP1R) agonists have transformed clinical care across type 2 diabetes, obesity, and hepatology. However, hepatologists and endocrinologists frequently… Read more: Unlocking Precision Medicine in Metabolic Health: Why GLP-1 Agonist Responses Vary and How AI is Solving the Puzzle
- Beyond the Tumor: How Fatty Liver Fuels Aggressive Cancer MetastasisAsk the author session What if the secret to understanding cancer’s aggressiveness lies not just within the tumor itself, but in the environment where it… Read more: Beyond the Tumor: How Fatty Liver Fuels Aggressive Cancer Metastasis
Living with NASH
Non-alcoholic steatohepatitis (NASH) is the consequence of abnormal fat accumulation in the liver leading to liver inflammation and damage. It is the most severe form of non-alcoholic liver disease (NAFLD), commonly called “fatty liver”. NASH is a worldwide epidemic disease affecting over 115 million people.
Still, NASH remains an under-diagnosed and consequently an underreported disease.
Many people live with NASH without knowing that they have a liver disease. The quality of life of these persons might be reduced due to their liver condition. Lifestyles can do a lot to improve NASH.
But changes in diet habits, regular physical activity are measures which can improve if not cure NASH.
